Physician

Eugene Muchnik, M.D.

According to 2025 Medicare claims, Eugene Muchnik, M.D. (NPI: 1811286024) practices hematology/oncology in the Williamsport, PA market, with the plurality of this provider's patient population coming from Lycoming, PA. This provider's primary affiliated billing organization is SUSQUEHANNA PHYSICIAN SERVICES (NPI: 1700962701; TIN: 232449454) and primary practice location at 17701-1909. Muchnik is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Muchnik's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 439 traditional Medicare patients, billed 1,594 HCPCS/CPT codes, and received $147,696 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,742 prescription claims across 338 beneficiaries totaling $10,897,441 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 55 claims. Open Payments data shows 38 records totaling $12,963. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $42,850 to $147,696. Similarly, Part D prescription costs have moved sharply higher in recent years, from $13,311 to $10,897,441. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	211	607	$42,850
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	198	383	$25,993
2019	277	740	$45,801
2020	277	518	$29,423
2021	397	1,055	$84,886
2022	390	976	$81,933
2023	420	1,145	$108,158
2024	439	1,594	$147,696

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	70	183	$13,311
2016	42	90	$109,546
2017	40	90	$64,475
2018	96	249	$316,069
2019	164	661	$947,799
2020	153	610	$1,682,943
2021	252	1,519	$5,585,089
2022	325	1,778	$8,066,649
2023	358	1,991	$8,473,833
2024	338	1,742	$10,897,441

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$956
2024	N/R	55	$1,522

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	73	73	$136
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	248	1,003	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	191	270	$66
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	40	43	$38
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	46	85	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	98	2,788	$1,557,689
Lenalidomide	Lenalidomide	106	2,926	$1,439,500
Calquence	Acalabrutinib Maleate	64	1,920	$879,489
Brukinsa	Zanubrutinib	54	1,620	$788,947
Pomalyst	Pomalidomide	32	896	$620,121

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	29	$1,208
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	26	$314

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$12,963	Mirati Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eugene Muchnik, M.D.?

Tedicare shows public-source Medicare data for Eugene Muchnik, M.D. (NPI 1811286024), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eugene Muchnik, M.D. have ACO affiliation data?

Eugene Muchnik, M.D. is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Eugene Muchnik, M.D.?

Eugene Muchnik, M.D. is linked to SUSQUEHANNA PHYSICIAN SERVICES (billing NPI 1700962701) in the available physician profile data.

Does Eugene Muchnik, M.D. have Open Payments data?

Eugene Muchnik, M.D. has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.